Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Feb:101:106272.
doi: 10.1016/j.cct.2021.106272. Epub 2021 Jan 7.

Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ahmad Al-Abdouh  1 , Anas Bizanti  2 , Mahmoud Barbarawi  3 , Ahmad Jabri  4 , Ashish Kumar  5 , Oluwaseun E Fashanu  2 , Safi U Khan  6 , Di Zhao  7 , Annukka A R Antar  8 , Erin D Michos  9
Affiliations
Meta-Analysis

Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ahmad Al-Abdouh et al. Contemp Clin Trials. 2021 Feb.

Abstract

Background: The nucleotide analogue prodrug remdesivir was among the first antiviral therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a meta-analysis to understand efficacy and safety.

Methods: We searched PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov databases (from January 1, 2020 to November 5, 2020). We included RCTs comparing the efficacy and safety of remdesivir to control/placebo in COVID-19. Two independent investigators abstracted data, assessed the quality of evidence, and rated the certainty of evidence.

Results: A total of 4 RCTs with 7334 patients with COVID-19 were included. At a follow-up of 28-29 days from randomization, very low certainty evidence showed that use of remdesivir compared with control group (placebo and/or standard of care) was not associated with a significant decrease in time to clinical improvement (standardized mean difference -0.80 day; [CI, -2.12, 0.53]). However, moderate certainty of evidence showed that remdesivir was associated with higher rates of recovered patients (risk difference [RD] 0.07 [0.05, 0.08]) and discharged patients (RD 0.07 [0.03, 0.11]) and lower rates of developing serious adverse events (RD -0.05 [-0.10, -0.01]) compared with control. Moderate and very low certainty of evidence showed there was no significant difference in deaths at 28-29 days follow-up (RD -0.01 [-0.03, 0.01]) and developing any adverse events (RD 0.01 [-0.17, 0.19]) between both groups, respectively.

Conclusion: Patients given remdesivir are more likely to demonstrate recovery and were associated with higher rates of hospital discharge, but not with significant reduction in mean time to clinical improvement or mortality.

Keywords: COVID-19; Remdesivir; SARS-Cov-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Details of the search results.
Fig. 2
Fig. 2
A. Forest plot of mean time to clinical improvement. B. Forest plot of recoveries. C. Forest plot of discharges from hospital. D. Forest plot of deaths. E. Forest plot of any serious adverse events. F. Forest plot of any adverse events.
See this image and copyright information in PMC

References

    1. Haleem A., Javaid M., Vaishya R. Effects of COVID-19 pandemic in daily life. Curr. Med. Res. Pract. 2020;10(2):78–79. doi: 10.1016/j.cmrp.2020.03.011. - DOI - PMC - PubMed
    1. Gordon C.J., Tchesnokov E.P., Woolner E., et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295(20):6785–6797. doi: 10.1074/jbc.RA120.013679. - DOI - PMC - PubMed
    1. Mulangu S., Dodd L.E., Davey R.T.J., et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 2019;381(24):2293–2303. doi: 10.1056/NEJMoa1910993. - DOI - PMC - PubMed
    1. Sheahan T.P., Sims A.C., Graham R.L., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 2017;9(396) doi: 10.1126/scitranslmed.aal3653. - DOI - PMC - PubMed
    1. Wang Y., Zhang D., Du G., et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (LondonEngland) 2020;395(10236):1569–1578. doi: 10.1016/S0140-6736(20)31022-9. - DOI - PMC - PubMed

Publication types

MeSH terms